Bolt Biotherapeutics, Inc. (BOLT)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Bolt Biotherapeutics, Inc. reported revenue of $7.70M, up 0.1% from the prior year. The company ran a net loss, with a net margin of -433.7%. It held $56.75M in total assets against $30.24M in total liabilities.
Key ratios (FY2025)
-469.3%
Operating margin
-433.7%
Net margin
-125.9%
Return on equity
+0.1%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $7.70M | $7.69M | $7.88M | $5.73M | $1.26M | $231.0K | — |
| Operating Income | -$36.11M | -$73.05M | -$76.20M | -$90.32M | -$92.79M | -$49.18M | — |
| Net Income | -$33.38M | -$63.12M | -$69.20M | -$88.10M | -$98.59M | -$60.73M | — |
| EPS (Diluted) | $-17.85 | $-33.06 | $-1.83 | $-2.36 | $-2.97 | — | — |
| Total Assets | $56.75M | $99.63M | $159.78M | $227.81M | $307.72M | $46.54M | — |
| Total Liabilities | $30.24M | $42.43M | $47.04M | $56.30M | $57.60M | $46.19M | — |
| Shareholders' Equity | $26.50M | $57.20M | $112.74M | $171.51M | $250.12M | -$104.95M | -$45.85M |
| Cash & Equivalents | $11.70M | $7.21M | $10.81M | $9.24M | $27.38M | $5.54M | — |
| Operating Cash Flow | -$39.85M | -$61.29M | -$69.53M | -$76.50M | -$57.07M | -$47.31M | — |
| Capital Expenditures | $72.0K | $41.0K | $206.0K | $1.95M | $2.34M | $3.26M | — |
| Shares Outstanding | 1.92M | 1.92M | 38.11M | 37.80M | 37.40M | 2.13M | — |